Type 2 diabetes mellitus
Not yet recruitingPhase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin
Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin
- Disease:Type 2 diabetes mellitus
- Substances:SemaglutideMaridebart Cafraglutide
Poland- Participants:18–64 years · 65+ years
- Substances:Semaglutide
- Sponsor:Amgen Inc.










